«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2017年第1期

页码:

116-119

栏目:

综述

出版日期:

2016-10-05

文章信息/Info

Title:

Research progress in renal sympathetic denervation in the treatment of hypertension and symptomatic atrial fibrillation

作者:

江 灿; 郭 军

(暨南大学附属第一医院心内科，广东 广州 510630)

Author(s):

JIANG Can;  GUO Jun

(Department of Cardiology, First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong, China)

关键词:

肾动脉去交感神经消融术; 心房颤动; 高血压

Keywords:

renal sympathetic denervation;  atrial fibrillation;  hypertension

分类号:

R544.1

DOI:

-

文献标识码:

A

摘要:

无论是高血压还是心房颤动(AF)药物治疗都很难达到理想的指标，而且其副作用的影响不容忽视，因而积极探索新型非药物治疗手段具有重要的现实意义。交感神经过度激活既是高血压发生、发展的重要机制，也参与AF的触发与维持。经皮导管肾脏去交感神经射频消融术（RSD）通过干预交感神经为治疗高血压伴症状性AF开辟了新的治疗途径。大量研究证实RSD治疗高血压、AF是安全有效的，还可治疗与交感神经过度激活相关的疾病，比如睡眠呼吸暂停综合症、心力衰竭、胰岛素抵抗等。本文就RSD治疗高血压病伴症状性AF的研究进展综述如下。

Abstract:

The desired therapy target is difficult to be achieved by only medicine for either hypertension or atrial fibrillation (AF) and the side effects cannot be ignored. Thus, it has important realistic significance to explore new non-pharmacological methods to treat hypertension and AF. Sympathetic overactivity is one important mechanism of hypertension and is involved in the triggering and maintenance of AF. Renal sympathetic denervation (RSD) is a novel therapy for patients with hypertension and symptomatic AF by intervening in the sympathetic nervous system. Many studies have confirmed that RSD is safe and effective in controlling blood pressure and treating AF. Moreover, RSD can treat other diseases associated with excessive sympathetic activation such as sleep apnea syndrome, heart failure and insulin resistance. This article reviews research progress of RSD therapy for patients with hypertension and symptomatic AF.

参考文献/References

[1]Verma A,Kilicaslan F,Pisano E,et al.Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction[J].Circulation,2005,112(5):627-635.
[2]Hering D,Lambert EA,Marusic P,et al.Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension[J].Hypertension,2013,61(2):457-464.
[3]Mahfoud F,Edelman ER,Bohm M.Catheter-based renal denervation is no simple matter:lessons to be learned from our anatomy?[J].J Am Coll Cardiol,2014,64(7):644-646.
[4]Zhou Q,Hu J,Guo Y,et al.Effect of the stellate ganglion on atrial fibrillation and atrial electrophysiological properties and its left-right asymmetry in a canine model[J].Exp Clin Cardiol,2013,18(1):38-42.
[5]Schotten U,Verheule S,Kirchhof P,et al.Pathophysiological mechanisms of atrial fibrillation:a translational appraisal[J].Physiol Rev,2011,91(1):265-325.
[6]Ng J,Villuendas R,Cokic I,et al.Autonomic remodeling in the eft atrium and pulmonary veins in heart failure: creation of a dynamic substrate for atrial fibrillation[J].Circ Arrhythm Electrophysiol,2011,4(3):388-396.
[7]Chen PS,Turker I.Epicardial adipose tissue and neural mechanisms of atrial fibrillation[J].Circ Arrhythm Electrophysiol,2012,5(4):618-620.
[8]Jayachandran JV,Sih HJ,Winkle W,et al.Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation[J].Circulation,2000,101(10):1185-1191.
[9]Burstein B,Nattel S.Atrial fibrosis:mechanisms and clinical relevance in atrial fibrillation[J].J Am Coll Cardiol,2008,51(8):802-809.
[10]Nyman Y,Von Hofsten K,Palm C,et al.Etomidate-Lipuro is associated with considerably less injection pain in children compared with propofol with added lidocaine[J].Br J Anaesth,2006,97(4):536-539.
[11]Parati G,Esler M.The human sympathetic nervous system:its relevance in hypertension and heart failure[J].Eur Heart J,2012,33(9):1058-1066.
[12]Pathak A,Girerd X,Azizi M,et al.Expert consensus:renal denervation for the treatment of arterial hypertension[J].Arch Cardiovasc Dis,2012,105(6-7):386-393.
[13]Krum H,Schlaich M,Whitbourn R,et al.Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].Lancet,2009,373(9671):1275-1281.
[14]Esler MD,Krum H,Sobotka PA,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J].Lancet,2010,376(9756):1903-1909.
[15]Liu M,Chen J,Liu C,et al.Catheter-based renal sympathetic denervation is effective in reducing office and ambulatory blood pressure in patients with resistant hypertension[J].Int J Cardiol,2014,172(1):259-260.
[16]Bhatt DL,Kandzari DE,O'Neill WW,et al.A controlled trial of renal denervation for resistant ypertension[J].N Engl J Med,2014,370(15):1393-1401.
[17]Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation:recommendations for patient selection,procedural techniques, patient management and follow-up,definitions,endpoints,and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation.Developed in partnership with the European Heart Rhythm Association(EHRA),a registered branch of the European Society of Cardiology(ESC)and the European Cardiac Arrhythmia Society(ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons(STS).Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association,the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society[J].Heart Rhythm,2012,9(4):632-696,e21.
[18]Linz D,Mahfoud F,Schotten U,et al.Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation[J].Hypertension,2013,61(1):225-231.
[19]Zhao Q,Yu S,Huang H,et al.Effects of renal sympathetic denervation on the development of atrial fibrillation substrates in dogs with pacing-induced heart failure[J].Int J Cardiol,2013,168(2):1672-1673.
[20]Mahfoud F,Urban D,Teller D,et al.Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial[J].Eur Heart J,2014,35(33):2224-2231b.
[21]Linz D,Mahfoud F,Schotten U,et al.Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea[J].Hypertension,2012,60(1):172-178.
[22]Witkowski A,Prejbisz A,Florczak E,et al.Effects of renal sympathetic denervation on blood pressure, sleep apnea course,and glycemic control in patients with resistant hypertension and sleep apnea[J].Hypertension,2011,58(4):559-565.
[23]Scherlag MA,Scherlag BJ.A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension[J].J Am Coll Cardiol,2013,62(12):1129-1130.
[24]Ahmed H,Miller MA,Dukkipati SR,et al.Adjunctive renal sympathetic denervation to modify hypertension as upstream therapy in the treatment of atrial fibrillation(H-FIB)study:clinical background and study design[J].J Cardiovasc Electrophysiol,2013,24(5):503-509.
[25]Ukena C,Mahfoud F,Spies A,et al.Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension[J].Int J Cardiol,2013,167(6):2846-2851.

备注/Memo

备注/Memo:

收稿日期：2015-10-13.
通讯作者：郭军，副主任医师，主要从事心脏电生理机制研究 Email：dr.guojun@163.com
作者简介：江灿，硕士生 Email：eudora12@163.com

常用功能

更新日期/Last Update: 2016-10-09